Does fructose consumption contribute to non-alcoholic fatty liver disease?
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic, animal, and clinical intervention literature without systematic search methods.
PubMed 22795319 · doi:10.1016/j.clinre.2012.06.005
What was done
The author reviewed animal studies, human intervention trials, and epidemiological literature examining the metabolic fate of fructose, its effects on hepatic de novo lipogenesis and insulin sensitivity, and its potential role in the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD).
What was found
In humans, fructose represents up to 10% of total energy intake in several Western countries. Human intervention trials show that fructose overfeeding increases fasting and postprandial plasma triglycerides by stimulating de novo lipogenesis and VLDL-TG secretion while reducing clearance. Intakes up to 200 g/day modestly decrease hepatic insulin sensitivity without affecting whole-body (muscle) insulin sensitivity. Short-term overfeeding significantly increases intrahepatic fat concentrations, though below thresholds seen in clinical NAFLD. The abstract provides no specific numerical effect sizes or p-values and reports no solid evidence of harm from moderate consumption.
Why it matters
This review clarifies that while extreme experimental fructose overfeeding induces hepatic lipid accumulation and dyslipidemia, evidence does not establish that typical, moderate dietary fructose consumption causes NAFLD.
Limits
The abstract describes a non-systematic narrative review without reported study counts, participant sample sizes, or pooled effect estimates. Available human data rely largely on short-term, supra-physiological overfeeding paradigms rather than long-term evaluations of habitual intake.
Cited by
- contradicts About 70% of ingested fructose is absorbed through the portal vein and metabolized by the liver into uric acid and triglycerides.